Maze Therapeutics
MAZE· Manufacturing· Fiscal year ends in December
CEO pay in FY2025
Jason Coloma, Ph.D. is the CEO of Maze Therapeutics and was paid $3.5M in FY2025 (Dec), down 41%.
PayNo stock prices for these years
Executives3
See all- 1Misbah TahirChief Financial OfficerFY2025
- 2Jason Coloma, Ph.D.Chief Executive OfficerFY2025
- 3Harold Bernstein, M.D., Ph.D.President, Research and Development and Chief Medical OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allMaze Therapeutics paid its 3 named executives $9.2M in total in FY2025 (Dec). CEO Jason Coloma, Ph.D. was paid $3.5M of that.
| Name | ||
|---|---|---|
| Misbah TahirChief Financial Officer | Not disclosed | |
| Jason Coloma, Ph.D.Chief Executive Officer | ||
| Harold Bernstein, M.D., Ph.D.President, Research and Development and Chief Medical Officer |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Maze Therapeutics. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Board5
See all- Charles Homcy, M.D.Director · 7 yr on the boardNot independentNominating and Corporate Governance—Paid as an executive
- Jonathan Lim, M.D.Director · 6 yr on the boardIndependentCompensation—Paid as an executive
- Richard H. Scheller, Ph.D.Director · 6 yr on the boardIndependent—Paid as an executive
- Daniel SpiegelmanDirector · 5 yr on the boardIndependentAudit (Chair), Nominating and Corporate Governance (Chair)—Paid as an executive
- Neil Kumar, Ph.D.Director · -1 yr on the boardIndependent—Paid as an executive
The board of the latest proxy (FY2025).
Shared directors
Activity
Filings3
See all| Proxy statement | DEF 14A | Apr 28, 2026 | FY2025 |
| Annual report | 10-K | Mar 25, 2026 | FY2025 |
| Annual report | 10-K | Mar 31, 2025 | FY2024 |
